Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma

OBJECTIVE: To investigate whether dose reductions in cisplatin due to renal dysfunction were associated with worse clinical outcomes in metastatic urothelial carcinoma (UC) patients. PATIENTS AND METHODS: One hundred and fifty one metastatic UC patients who received first‐line gemcitabine plus cispl...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Tetsushi, Kikuchi, Eiji, Ide, Hiroki, Umezawa, Yuta, Takahashi, Takayuki, Izawa, Mizuki, Hakozaki, Kyohei, Shigeta, Keisuke, Ogihara, Koichiro, Kobayashi, Hiroaki, Kanai, Kunimitsu, Maeda, Takahiro, Yoshimine, Shunsuke, Mizuno, Ryuichi, Nishimoto, Koshiro, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988766/
https://www.ncbi.nlm.nih.gov/pubmed/35474877
http://dx.doi.org/10.1002/bco2.81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988766/
https://www.ncbi.nlm.nih.gov/pubmed/35474877
http://dx.doi.org/10.1002/bco2.81

Ejemplares similares